A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers

Type of Cancer
Solid Tumor

Site
Bethesda

Sponsor
Incyte Corporation

Protocol Number
INCB 24360-202

To Learn More Call
201-510-0910